Novartis AG

NVS

Cena:

Valuace

Růst

Zdraví

Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři

Souhrn

Finanční data

Pro investory

Předpovědi

Zprávy

Dividendy

Zisky

Návštěvnost webu

Akcionáři

Zprávy

Zahraniční články

Tiskové zprávy

Dokumenty ke stáhnutí

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

5:36 12-06-2026

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy...

Novartis says rare muscle disease drug shows promise in early trial

17:41 11-06-2026

Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion take...

Novartis Reports Positive Data for Neuromuscular Disorder Drug

14:26 11-06-2026

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a d...

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

9:14 11-06-2026

Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study eval...

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

1:00 11-06-2026

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints o...

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

7:00 10-06-2026

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

3:00 08-06-2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Al...

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

6:15 04-06-2026

Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidn...

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

11:30 03-06-2026

Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rh...

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

1:15 01-06-2026

Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading...

Experimental Novartis radiopharma drug shows promise in early study

7:16 31-05-2026

Novartis said on Sunday that early data from ‌its experimental actinium-based drug showed signs of...

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

1:15 26-05-2026

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at th...

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

1:15 21-05-2026

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsor...

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

15:30 17-05-2026

Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved pr...

Implied Volatility Surging for Novartis Stock Options

10:05 13-05-2026

Investors need to pay close attention to NVS stock based on the movements in the options market late...

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

9:00 07-05-2026

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground o...

Novartis to cut 220 jobs as it closes German site

8:16 05-05-2026

Swiss drugmaker Novartis said on Tuesday ‌that it is set to cut around 220 jobs ⁠in ...

Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100

17:06 30-04-2026

On April 30, 2026, Novartis AG (NVS) shares rose 3.4% today, bringing the current price to $147.85. ...

Concurrent Investment Advisors LLC Grows Position in Novartis AG $NVS

14:10 29-04-2026

Concurrent Investment Advisors LLC raised its holdings in shares of Novartis AG (NYSE: NVS) by 36.6%...

Novartis: Revenue Lags In Q1, Outlook Unchanged

15:18 28-04-2026

Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year g...

NOVARTIS VANRAFIA® PHASE III DATA SUPPORT SLOWING OF KIDNEY FUNCTION DECLINE IN PATIENTS WITH IGA NEPHROPATHY

13-02-2026

BASEL, FEBRUARY 13, 2026 – NOVARTIS TODAY ANNOUNCED FINAL RESULTS FROM THE PHASE III ALIGN STUDY S...

Více zde

NOVARTIS DELIVERED HIGH SINGLE-DIGIT SALES GROWTH, ACHIEVED 40% CORE MARGIN AND FURTHER ADVANCED THE PIPELINE IN 2025

04-02-2026

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FULL YEAR NET SALES GREW +8% (CC 1 , +8% USD) WITH CORE O...

Více zde

ZONSEN PEPLIB BIOTECH AND NOVARTIS SIGN WORLDWIDE LICENSE AGREEMENT REGARDING RADIOLIGAND THERAPY ASSET

13-01-2026

ZHUZHOU, CHINA & BOSTON--(BUSINESS WIRE)--ZONSEN PEPLIB BIOTECH INC. (“PEPLIB”) TODAY ANNOUNCED ...

Více zde

NOVARTIS TO ADD RADIOLIGAND THERAPY MANUFACTURING FACILITY IN WINTER PARK, FLORIDA, FOURTH IN US TO SERVE PATIENTS AND ADVANCE $23 BILLION INVESTMENT

09-01-2026

BASEL, JANUARY 9, 2026 – NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, TODAY ANNOUNCED ...

Více zde

NOVARTIS AND US GOVERNMENT REACH AGREEMENT ON LOWERING DRUG PRICES IN THE US

19-12-2025

BASEL, DECEMBER 19, 2025 – NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, TODAY ANNOUNCE...

Více zde

SALESFORCE'S AGENTFORCE LIFE SCIENCES SELECTED BY NOVARTIS TO DRIVE MORE PERSONALIZED CUSTOMER ENGAGEMENT GLOBALLY

17-12-2025

SAN FRANCISCO--(BUSINESS WIRE)--SALESFORCE (NYSE: CRM), THE WORLD'S #1 AI CRM, ANNOUNCED TODAY THAT ...

Více zde

NOVARTIS BREAKS GROUND ON FLAGSHIP MANUFACTURING HUB IN NORTH CAROLINA

12-12-2025

EAST HANOVER, DECEMBER 12, 2025 – NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, BROKE G...

Více zde

NOVARTIS IANALUMAB SIGNIFICANTLY EXTENDS DISEASE CONTROL IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA WITH ONLY FOUR ONCE-MONTHLY DOSES

09-12-2025

BASEL, DECEMBER 9, 2025 – NOVARTIS TODAY ANNOUNCED POSITIVE RESULTS FROM VAYHIT2, A PHASE III TR...

Více zde

1 IN 4 METASTATIC BREAST CANCER PATIENTS TREATED WITH NOVARTIS KISQALI® REMAIN PROGRESSION-FREE BEYOND 4 YEARS

09-12-2025

BASEL, DECEMBER 9, 2025 – NOVARTIS TODAY ANNOUNCED RESULTS SHOWING THAT ONE IN FOUR PATIENTS WITH ...

Více zde

RELATION ANNOUNCES STRATEGIC COLLABORATION WITH NOVARTIS TO ADVANCE THERAPEUTICS FOR ATOPIC DISEASES

09-12-2025

LONDON, DEC. 09, 2025 (GLOBE NEWSWIRE) -- RELATION TODAY ANNOUNCED A MULTI-PROGRAM, STRATEGIC COLLAB...

Více zde

NOVARTIS DATA UNDERSCORE PIONEERING SCIENTIFIC INNOVATION IN HEMATOLOGY AND ONCOLOGY AT ASH AND SABCS

25-11-2025

BASEL, NOVEMBER 25, 2025 – NOVARTIS WILL PRESENT DATA FROM OVER 70 ABSTRACTS, INCLUDING INVESTIGA...

Více zde

MUSCULAR DYSTROPHY ASSOCIATION CALLS FDA APPROVAL OF NOVARTIS' ITVISMA (ONASEMNOGENE ABEPARVOVEC-BRVE) A MAJOR STEP FORWARD FOR THE SPINAL MUSCULAR ATROPHY COMMUNITY

24-11-2025

THE ONLY GENE REPLACEMENT THERAPY FOR CHILDREN TWO YEARS AND OLDER, TEENS, AND ADULTS WITH SPINAL MU...

Více zde

NOVARTIS RECEIVES FDA APPROVAL FOR ITVISMA®, THE ONLY GENE REPLACEMENT THERAPY FOR CHILDREN TWO YEARS AND OLDER, TEENS, AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA)

24-11-2025

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR ITVISMA (ONASEMNOGENE ABEPARVOVEC-BRVE) DEMONSTRATED IMPR...

Více zde

NOVARTIS PROJECTS +5-6% CC SALES CAGR 2025-2030, WITH LONG-TERM GROWTH BACKED BY 30+ POTENTIAL HIGH-VALUE PIPELINE ASSETS

20-11-2025

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR MID-TERM SALES GUIDANCE ROLLED FORWARD TO +5-6% CC CAGR F...

Více zde

NOVARTIS ANNOUNCES PLANS TO BUILD FLAGSHIP MANUFACTURING HUB IN NORTH CAROLINA

19-11-2025

BASEL, NOVEMBER 19, 2025 – NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, TODAY ANNOUNCE...

Více zde

THE RACE FOR THE GLOBAL RADIOTHERAPY CANCER MARKET; ACTINIUM PHARMACEUTICALS' (ATNM) BIG BET

17-11-2025

VANCOUVER, KELOWNA, AND DELTA, BRITISH COLUMBIA--(NEWSFILE CORP. - NOVEMBER 17, 2025) - INVESTORIDEA...

Více zde

INTERIM REPORT FOR THE PERIOD JULY - SEPTEMBER 2025: BIOARCTIC

13-11-2025

STOCKHOLM , NOV. 13, 2025 /PRNEWSWIRE/ -- BROADENING OUR PORTFOLIO WITH NEW PROJECTS AND PARTNERSHIP...

Více zde

NEW NOVARTIS DATA AT ASN KIDNEY WEEK AND AHA SCIENTIFIC SESSIONS DEMONSTRATE MOMENTUM OF BROAD CRM PORTFOLIO AND PIPELINE

04-11-2025

BASEL, NOVEMBER 4, 2025 – NOVARTIS WILL PRESENT NEW DATA FROM 33 ABSTRACTS ACROSS ITS CARDIOVASCUL...

Více zde

MEHARRY AND NOVARTIS PARTNER ON HEART INITIATIVE FOR HEALTHIER COMMUNITIES

03-11-2025

NASHVILLE, TENN.--(BUSINESS WIRE)--THE SCHOOL OF GLOBAL HEALTH AT MEHARRY MEDICAL COLLEGE, IN PARTNE...

Více zde

NOVARTIS IANALUMAB FIRST DRUG TO REDUCE DISEASE ACTIVITY AND PATIENT BURDEN IN SJÖGREN'S DISEASE PHASE III TRIALS

29-10-2025

BASEL, OCTOBER 29, 2025 – NOVARTIS TODAY PRESENTED NEW IANALUMAB DATA IN SJÖGREN'S DISEASE, THE S...

Více zde

NOVARTIS COMPLETES ACQUISITION OF TOURMALINE BIO

28-10-2025

BASEL, OCTOBER 28, 2025 - NOVARTIS TODAY ANNOUNCED THAT IT HAS SUCCESSFULLY COMPLETED ITS ACQUISITIO...

Více zde

NOVARTIS ANNOUNCES EXPIRATION OF TOURMALINE BIO TENDER OFFER

28-10-2025

BASEL, OCTOBER 28 2025 - NOVARTIS TODAY ANNOUNCED THAT ITS PREVIOUSLY ANNOUNCED TENDER OFFER (THE �...

Více zde

NOVARTIS DELIVERS SOLID SALES AND CORE OPERATING INCOME GROWTH WITH STRONG PIPELINE PROGRESS IN Q3; REAFFIRMS FY 2025 GUIDANCE

28-10-2025

Q3 NET SALES GREW +7% (CC1, +8% USD) AND CORE OPERATING INCOME1 GREW +7% (CC, +6% USD). SALES GROWTH...

Více zde

AVIDITY BIOSCIENCES ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG

26-10-2025

NOVARTIS TO ACQUIRE AVIDITY FOR USD 72.00 PER SHARE IN CASH FOR TOTAL EQUITY VALUE OF APPROXIMATELY ...

Více zde

NOVARTIS AGREES TO ACQUIRE AVIDITY BIOSCIENCES, AN INNOVATOR IN RNA THERAPEUTICS, STRENGTHENING ITS LATE-STAGE NEUROSCIENCE PIPELINE

26-10-2025

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR TRANSACTION STRENGTHENS NEUROSCIENCE FRANCHISE FOR NOVART...

Více zde

NOVARTIS SHOWCASES SIGNIFICANT IMMUNOLOGY ADVANCEMENTS IN ACR CONGRESS WITH NEW DATA IN COMPLEX AUTOIMMUNE DISEASES

25-10-2025

BASEL, OCTOBER 25, 2025 – NOVARTIS ANNOUNCED TODAY PLANS TO PRESENT DATA FROM 27 COMPANY- OR INVES...

Více zde

NOVARTIS COSENTYX® MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN PHASE III TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA (PMR)

22-10-2025

BASEL, OCTOBER 22, 2025 – NOVARTIS TODAY ANNOUNCED THAT COSENTYX® (SECUKINUMAB) MET THE PRIMARY E...

Více zde

NOVARTIS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD OF TOURMALINE BIO TENDER OFFER

22-10-2025

BASEL, OCTOBER 22, 2025 - NOVARTIS TODAY ANNOUNCED THE EXPIRATION OF THE WAITING PERIOD UNDER THE H...

Více zde

PSMADDITION DATA SHOW NOVARTIS PLUVICTO™ DELAYS PROGRESSION TO END-STAGE PROSTATE CANCER

19-10-2025

BASEL, OCTOBER 19, 2025 – NOVARTIS TODAY PRESENTS NEW PLUVICTO™ (LUTETIUM (177LU) VIPIVOTIDE TET...

Více zde

NOVARTIS KISQALI® 5-YEAR NATALEE DATA DEMONSTRATE 28% REDUCTION IN RISK OF RECURRENCE IN THE BROADEST EARLY BREAST CANCER PATIENT POPULATION

17-10-2025

BASEL, OCTOBER 17, 2025 – NOVARTIS TODAY ANNOUNCED RESULTS FROM THE FIVE-YEAR ANALYSIS OF THE PIVO...

Více zde

Dokumenty nejsou k dispozici